adrenal gland disease: A disease involving the adrenal gland.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
242 |
4. Check minimum number of eventsNone |
242 |
5. Include endpointsNone |
242 |
6. Filter based on genotype QC (FinnGen only) |
214 |
Control definitions (FinnGen only)
- Control exclude
- E4_ENDOGLAND
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- E27
- Name in latin
- Alia hyperfunctio adrenocorticalis
Similar endpoints
↥List of similar endpoints to
Other adrenocortical overactivity
based on the number of shared cases.
Similar with more cases:
- Other disorders of adrenal gland
- Exclusions for E4_PCOS_BROAD
- Disorders of other endocrine glands
- Endocrine, nutritional and metabolic diseases
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 4574 | 3566 | 1002 |
| Only index persons | 3335 | 2615 | 720 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.09 | 0.10 | 0.03 |
| Only index persons | 0.08 | 0.10 | 0.03 |
| Median age at first event (years) | |||
| Whole population | 7.91 | 7.69 | 8.52 |
| Only index persons | 8.08 | 7.85 | 8.90 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 214 | 176 | 38 |
| Unadjusted period prevalence (%) | 0.05 | 0.06 | 0.02 |
| Median age at first event (years) | 17.40 | 8.59 | 58.19 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 228
- Matched controls
- 2280
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
E27.0
ICD-10 Finland
Other adrenocortical overactivity
9951.2
283.3
211
*
H02AB09
ATC
hydrocortisone; systemic
27.7
82.3
60
29
NK6MA
NOMESCO Finland
Measurement of bone age from hand and elbow using X-ray
14.6
37.5
36
29
105
Kela drug reimbursment
Adrenal cortical hypofunction
+∞
29.8
28
*
E27.1
ICD-10 Finland
Primary adrenocortical insufficiency
+∞
26.6
25
*
H02AA02
ATC
fludrocortisone; oral
89.1
22.1
24
*
D44.1
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Adrenal gland
218.2
19.9
20
*
Z03.80
ICD-10 Finland
Observation for other suspected diseases and conditions
8.4
19.5
27
36
E27.4
ICD-10 Finland
Other and unspecified adrenocortical insufficiency
+∞
17.9
17
*
E30.1
ICD-10 Finland
Precocious puberty
182.8
16.7
17
*
BCA31
NOMESCO Finland
Endoscopic unilateral adrenalectomy
+∞
15.8
15
*
25508
ICD-8 Finland
Diseases of adrenal glands, Hyperfunctio adrenocorticalis alia
+∞
13.7
13
*
NK6QA
NOMESCO Finland
Measurement of bone density from two or more locations with X-ray
5.3
13.0
28
59
D35.0
ICD-10 Finland
Benign neoplasm: Adrenal gland
74.1
12.7
14
*
E27.3
ICD-10 Finland
Drug-induced adrenocortical insufficiency
+∞
10.5
10
*
AA4CG
NOMESCO Finland
Extensive MRI examination of sella turcica with high intensity magnet
42.1
10.1
12
*
G47.3
ICD-10 Finland
Sleep apnoea
3.2
10.0
44
157
E24.9
ICD-10 Finland
Cushing syndrome, unspecified
+∞
9.4
9
*
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
2.6
8.8
63
291
D35.2
ICD-10 Finland
Benign neoplasm: Pituitary gland
52.0
8.7
10
*
L68.0
ICD-10 Finland
Hirsutism
93.4
8.5
9
*
E24.0
ICD-10 Finland
Pituitary-dependent Cushing disease
+∞
8.4
8
*
E24.8
ICD-10 Finland
Other Cushing syndrome
+∞
8.4
8
*
A09
ICD-10 Finland
Other gastroenteritis and colitis of infectious and unspecified origin
2.4
8.3
72
363
E66.00
ICD-10 Finland
Metabolic syndrome
5.1
8.3
18
38
R5110
NOMESCO Finland
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
3.3
7.9
32
108
H02AB07
ATC
prednisone; oral
3.5
7.9
29
92
C03CA01
ATC
furosemide; systemic
2.8
7.7
42
168
Z51.80
ICD-10 Finland
Manipulation of puberty development with hormone therapy
+∞
7.3
7
*
E27.5
ICD-10 Finland
Adrenomedullary hyperfunction
+∞
7.3
7
*
E89.6
ICD-10 Finland
Postprocedural adrenocortical(-medullary) hypofunction
+∞
7.3
7
*
M05BA04
ATC
alendronic acid; oral
6.5
6.6
16
26
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
2.8
6.5
35
139
E34.45
ICD-10 Finland
Abnormal growth increase
71.8
6.5
7
*
H03AA01
ATC
levothyroxine sodium; systemic
2.4
6.4
51
246
B01AB05
ATC
enoxaparin; parenteral
2.3
6.3
55
275
E30.8
ICD-10 Finland
Other disorders of puberty
+∞
6.3
6
*
E27.2
ICD-10 Finland
Addisonian crisis
+∞
6.3
6
*
BCA30
NOMESCO Finland
Unilateral adrenalectomy
+∞
6.3
6
*
E22.80
ICD-10 Finland
Central precocious puberty
+∞
6.3
6
*
M01AH01
ATC
celecoxib; oral
3.1
6.3
28
100
WX002
NOMESCO Finland
Sedation and analgesia
2.6
6.2
41
180
Z00.4
ICD-10 Finland
General psychiatric examination, not elsewhere classified
2.3
6.1
54
272
NA3AA
NOMESCO Finland
Lumbar spine X-ray examination without contrast
3.5
6.0
21
64
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
44
28
19.23
52.60
2.4
1.8
107.35
18.37
ng/l
1.81
44
28
41
89
5.40
18.59
3.2
1.9
4.41
8.97
nmol/l
2.60
36
83
42
110
4.45
15.11
2.3
1.6
10.37
7.63
u/l
0.49
23
73
44
136
3.77
12.55
2.1
1.6
14.78
16.16
iu/l
0.09
25
101
16
7
24.43
11.74
1.8
1.0
236.06
66.43
nmol/24h
—
16
7
40
192
2.31
4.99
2.8
1.9
—
—
—
0
0
17
51
3.52
4.99
1.4
1.2
—
—
—
0
0
50
267
2.12
4.81
2.9
2.0
—
—
—
0
0
119
859
1.81
4.60
12.1
8.1
1.22
1.22
mmol/l
0.09
109
769
12
23
5.44
4.52
1.6
1.9
—
—
—
0
0
11
20
5.72
4.34
11.7
4.0
13.81
6.27
pmol/l
0.78
11
20
25
104
2.58
4.23
11.4
3.0
1.23
1.23
mmol/l
0.18
25
95
117
863
1.73
4.02
4.2
2.8
74.00
69.61
nmol/l
0.94
109
798
37
188
2.16
4.02
2.9
1.9
—
—
—
0
0
14
37
3.96
3.97
1.6
1.7
—
—
—
0
0
13
34
3.99
3.76
1.5
1.6
—
—
—
0
0
38
201
2.07
3.72
9.5
7.9
105.13
104.91
mmol/l
0.12
38
201
15
51
3.08
3.65
1.7
1.6
—
—
—
0
0
79
544
1.69
3.36
5.3
3.2
2.36
2.37
mmol/l
0.44
73
502
29
144
2.16
3.33
7.2
8.7
13.84
13.77
kpa
0.02
29
139
29
144
2.16
3.33
7.2
8.7
5.36
5.18
kpa
0.38
29
139
71
478
1.70
3.27
2.9
2.3
—
—
—
0
0
14
49
2.98
3.25
1.6
1.4
—
—
—
0
0
14
49
2.98
3.25
1.6
1.4
—
—
—
0
0
206
1854
2.15
3.02
7.1
5.0
1.92
1.83
mu/l
0.49
201
1740
187
1633
1.81
2.98
6.5
4.2
14.37
14.39
pmol/l
0.03
176
1488
15
58
2.70
2.94
1.7
1.2
—
—
—
0
0
29
153
2.03
2.86
1.3
1.4
270.22
267.68
miu/ml
0.01
13
77
22
104
2.23
2.85
2.7
1.7
—
—
—
0
0
15
59
2.65
2.85
2.2
1.8
—
—
—
0
0
171
1465
1.67
2.83
3.8
3.4
1.24
1.17
mmol/l
0.74
163
1378
28
147
2.03
2.80
7.4
8.6
0.05
0.53
mmol/l
0.27
23
120
19
85
2.35
2.79
1.7
1.7
3.89
10.02
u/ml
—
7
19
15
60
2.61
2.76
1.7
1.2
—
—
—
0
0
107
827
1.55
2.72
8.0
6.3
11.76
12.14
umol/l
0.05
101
781
58
390
1.65
2.63
2.6
3.0
0.96
1.67
mg/l
0.99
40
277
49
318
1.69
2.53
3.9
4.2
851.63
969.47
ng/l
0.15
40
259
36
215
1.80
2.48
1.3
1.3
325.03
112.80
u/ml
—
9
81
87
653
1.54
2.47
2.2
1.8
91.74
96.21
pmol/l
0.41
48
346
37
224
1.78
2.44
3.0
4.2
4.29
6.51
umol/l
0.97
32
194
14
58
2.51
2.42
1.4
1.2
—
—
—
0
0
165
1432
1.55
2.28
6.1
4.6
37.35
37.55
mmol/mol
0.11
159
1363
30
174
1.83
2.27
1.8
1.3
117.36
414.47
u/ml
1.18
30
165
36
221
1.75
2.26
8.4
6.2
1.82
0.58
mmol/l
1.75
29
169
41
262
1.69
2.24
4.0
2.6
2.41
2.50
g/l
0.43
41
240
177
1567
1.58
2.17
4.3
3.8
1.45
1.48
mmol/l
0.47
169
1475
13
55
2.45
2.16
2.2
3.0
1.25
2.41
index
—
8
29
181
1613
1.59
2.13
4.5
3.6
5.56
5.57
mmol/l
0.03
171
1484
178
1583
1.57
2.09
4.4
3.9
4.42
4.53
mmol/l
0.94
172
1501
6
15
4.08
2.05
1.3
1.4
—
—
—
0
0
6
15
4.08
2.05
1.3
1.4
—
—
—
0
0
6
15
4.08
2.05
1.5
1.4
—
—
—
0
0
6
15
4.08
2.05
1.3
1.4
—
—
—
0
0
148
1273
1.46
1.99
11.8
6.8
88.83
84.76
u/l
0.38
143
1198
6
16
3.82
1.94
1.3
1.8
—
—
—
0
0
6
16
3.82
1.94
1.3
1.8
—
—
—
0
0
6
16
3.82
1.94
1.3
1.8
—
—
—
0
0
6
16
3.82
1.94
1.5
1.4
—
—
—
0
0
6
16
3.82
1.94
1.5
1.4
—
—
—
0
0
177
1582
1.53
1.93
4.7
4.2
2.57
2.66
mmol/l
0.83
170
1495
7
22
3.25
1.89
1.4
2.0
—
—
—
0
0
64
475
1.48
1.85
3.9
3.2
34.23
33.20
ng/l
0.03
41
250
7
23
3.11
1.81
1.1
1.2
—
—
—
0
0
142
1224
1.42
1.80
4.0
3.3
35.86
32.24
u/l
0.37
137
1175
15
74
2.10
1.79
1.7
1.3
—
—
—
0
0
42
289
1.56
1.72
3.9
2.6
11.98
13.99
umol/l
1.03
42
274
141
1220
1.41
1.71
11.6
9.1
4.30
3.85
e9/l
1.75
125
1029
41
281
1.56
1.70
5.5
6.2
0.58
1.19
mmol/l
0.57
33
234
21
121
1.81
1.65
1.6
1.4
0.48
0.27
mg/l
—
6
47
13
63
2.13
1.63
2.5
1.9
—
—
—
0
0
5
14
3.63
1.62
1.2
1.1
—
—
—
0
0
10
43
2.39
1.61
2.9
1.9
—
—
—
0
0
76
600
1.40
1.55
5.8
3.3
0.26
0.33
e6/l
0.24
60
414
6
21
2.91
1.51
1.2
2.2
—
—
—
0
0
9
38
2.42
1.47
2.7
1.7
—
—
—
0
0
9
40
2.30
1.42
1.1
1.0
—
—
—
0
0
9
41
2.24
1.38
1.8
1.3
—
—
—
0
0
37
263
1.49
1.32
3.3
5.8
30.21
29.97
s
0.12
37
257
15
85
1.82
1.26
2.9
1.6
—
—
—
0
0
8
154
0.50
1.19
1.1
1.7
—
—
—
0
0
13
73
1.83
1.13
1.7
1.3
—
—
—
0
0
7
30
2.37
1.13
1.6
1.7
—
—
—
0
0
15
89
1.73
1.10
4.4
5.1
0.69
0.60
%
0.62
15
89
40
300
1.40
1.09
2.5
2.3
3707.34
6530.19
u/l
0.32
12
115
6
121
0.48
1.09
1.3
1.5
59.75
52.58
ug/l
—
6
121
16
98
1.68
1.06
2.2
2.7
55.75
82.79
ml/min/173m2
—
8
38
197
1865
1.41
1.00
26.6
12.5
139.69
139.51
mmol/l
0.55
197
1821
54
433
1.32
0.98
1.7
1.5
21.72
19.61
nmol/l
0.36
46
376
35
262
1.40
0.97
11.4
10.2
24.55
24.58
mmol/l
0.01
35
262
150
1371
1.28
0.96
5.9
4.3
—
238.83
—
0
23
96
833
1.26
0.95
2.5
2.1
—
—
—
0
0
122
1092
1.25
0.91
5.7
3.6
0.00
0.00
estimate
-0.00
27
243
123
1103
1.25
0.90
5.7
3.7
0.00
0.00
estimate
-0.00
28
234
15
95
1.62
0.90
12.1
10.5
95.89
94.85
%
1.05
15
95
69
579
1.27
0.89
6.5
3.5
0.10
0.00
estimate
0.49
29
231
71
598
1.27
0.89
2.7
2.5
2.56
2.59
mg/l
0.04
66
517
6
30
2.03
0.87
3.3
1.7
—
—
—
0
0
16
104
1.58
0.87
12.8
11.3
1.46
1.04
mg/l
1.08
16
97
15
96
1.60
0.86
1.5
1.4
—
—
—
0
0
153
1416
1.24
0.80
5.6
4.1
12.16
8.80
mm/h
2.15
143
1317
11
66
1.70
0.80
2.3
2.3
—
—
—
0
0
13
82
1.62
0.80
1.5
1.6
—
—
—
0
0
6
33
1.84
0.79
1.3
1.1
—
—
—
0
0
91
799
1.23
0.79
5.6
3.3
0.00
0.01
estimate
0.80
23
204
190
1806
1.31
0.78
25.7
15.5
13.55
13.25
%
1.85
185
1787
54
642
0.79
0.76
2.2
2.5
—
—
—
0
0
122
1107
1.22
0.76
5.6
3.6
0.00
0.00
estimate
-0.00
29
241
13
84
1.58
0.73
1.5
1.6
154.40
124.23
au/ml
—
5
33
89
787
1.21
0.71
1.6
1.8
0.78
2.62
u/ml
1.89
21
192
166
1561
1.23
0.69
22.0
10.4
95.01
96.88
ml/min/173m2
0.37
151
1349
18
128
1.44
0.68
1.2
1.2
5.86
3.44
u/ml
0.34
11
81
45
371
1.27
0.67
5.6
4.2
12.41
13.60
mg/mmol
0.07
33
261
5
28
1.80
0.66
1.2
1.8
—
—
—
0
0
5
28
1.80
0.66
1.4
1.5
0.62
0.50
e9/l
—
5
28
205
1980
1.35
0.65
22.5
12.2
20.74
22.60
mg/l
0.46
175
1542
15
104
1.47
0.64
1.3
1.5
—
—
—
0
0
10
63
1.61
0.63
2.2
2.1
—
—
—
0
0
9
138
0.64
0.63
1.3
1.7
—
—
—
0
0
0
22
0.00
0.59
0.0
2.7
—
3.18
—
0
10
16
117
1.40
0.54
1.5
1.7
—
—
—
0
0
59
671
0.84
0.53
2.6
2.7
—
—
—
0
0
15
202
0.72
0.53
1.7
1.4
—
—
—
0
0
18
135
1.36
0.53
3.0
2.6
—
—
—
0
0
39
327
1.23
0.52
1.4
1.3
47.29
19.09
iu/ml
—
9
77
44
375
1.21
0.50
3.6
3.1
2.24
4.29
e6/l
1.13
21
169
7
46
1.54
0.48
1.7
1.8
—
—
—
0
0
100
919
1.16
0.48
3.4
2.8
—
—
estimate
—
0
0
7
47
1.50
0.48
1.4
1.4
—
—
—
0
0
37
435
0.82
0.47
1.8
1.6
—
—
—
0
0
37
312
1.22
0.47
1.5
1.3
1.53
8.11
u/ml
1.66
13
129
23
183
1.29
0.47
1.8
1.4
—
—
—
0
0
23
185
1.27
0.44
6.7
5.3
225.57
254.59
u/l
0.80
23
180
45
391
1.19
0.43
3.7
3.0
1.28
1.02
e6/l
0.17
21
180
5
33
1.53
0.41
1.2
2.3
0.00
0.00
g/l
—
5
33
0
15
0.00
0.41
0.0
1.3
—
127.23
—
0
15
0
17
0.00
0.41
0.0
1.0
—
—
—
0
0
0
18
0.00
0.40
0.0
1.2
—
69.22
—
0
18
5
36
1.40
0.38
2.4
2.0
—
—
—
0
0
6
45
1.34
0.34
2.2
1.3
365.33
316.39
mu/l
—
6
36
10
74
1.37
0.33
1.6
1.5
—
—
—
0
0
16
129
1.26
0.31
1.8
1.4
—
—
—
0
0
12
148
0.80
0.25
1.7
1.5
1.06
0.91
ratio
—
7
92
12
148
0.80
0.25
1.7
1.5
0.69
1.24
ratio
—
7
92
12
148
0.80
0.25
1.7
1.5
0.84
1.23
ratio
—
7
92
66
616
1.10
0.23
5.5
2.8
0.00
0.01
estimate
0.80
25
201
221
2188
1.33
0.23
31.0
18.5
4.55
4.49
e12/l
1.13
214
2130
0
10
0.00
0.21
0.0
1.3
—
—
—
0
0
0
10
0.00
0.21
0.0
2.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.6
—
—
—
0
0
0
14
0.00
0.20
0.0
1.1
—
0.97
—
0
8
16
184
0.86
0.18
1.3
1.7
2.77
3.17
mmol/l
—
10
127
7
62
1.13
0.17
3.0
2.5
0.62
0.51
nmol/l
—
7
53
55
517
1.08
0.17
4.3
3.2
1.02
1.02
kg/l
0.06
36
318
13
111
1.18
0.16
1.2
1.1
0.57
1.73
u/ml
—
6
73
176
1728
1.08
0.16
4.6
4.0
—
—
—
0
0
48
510
0.93
0.15
2.6
2.3
—
—
—
0
0
12
139
0.86
0.14
1.5
1.5
—
—
—
0
0
31
290
1.08
0.11
4.3
3.1
171.88
370.73
ng/l
0.50
16
168
15
165
0.90
0.09
4.7
5.2
29.94
23.20
%
—
8
87
200
1983
1.07
0.08
27.1
13.2
72.44
65.60
umol/l
1.52
200
1955
43
449
0.95
0.08
2.4
2.1
—
—
—
0
0
7
67
1.05
0.08
1.3
1.1
1.36
1.58
g/l
—
7
67
6
71
0.84
0.08
1.0
1.7
—
—
—
0
0
9
85
1.06
0.07
1.0
1.2
—
—
—
0
0
11
99
1.12
0.06
1.3
1.4
—
—
—
0
0
25
241
1.04
0.03
1.0
1.1
—
—
—
0
0
14
139
1.01
0.00
8.6
5.0
—
—
—
0
0
24
237
1.01
0.00
1.2
1.8
2.99
3.15
ratio
0.26
17
177
22
217
1.02
0.00
6.5
5.7
4.32
1.98
ug/l
0.46
22
192
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.8
—
1.22
—
0
5
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
3.4
—
—
—
0
0
6
59
1.02
-0.00
1.3
1.8
—
—
—
0
0
0
5
0.00
-0.00
0.0
11.0
—
—
—
0
0
7
69
1.01
-0.00
1.3
1.2
0.76
0.86
g/l
—
7
69
0
7
0.00
-0.00
0.0
1.9
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.4
—
—
—
0
0
5
51
0.98
-0.00
5.0
4.2
18.00
3763.33
u/ml
—
5
46
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
1.47
—
0
7
Mortality – FinRegistry
↥Association
Association between endpoint E4_ADREACT and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| E4_ADREACT | 4.569 [3.1, 6.73] | < 0.001 |
| Birth year | 0.992 [0.98, 1.0] | 0.084 |
During the follow-up period (1.1.1998 — 31.12.2019), 65 out of 2952 females with E4_ADREACT died.
Males
No dataMortality risk
Mortality risk for people of age
years, who have E4_ADREACT.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.47% | No data |
| 5 | 2.272% | No data |
| 10 | 5.762% | No data |
| 15 | 11.548% | No data |
| 20 | 18.618% | No data |
Relationships between endpoints
↥Index endpoint: E4_ADREACT – Other adrenocortical overactivity
GWS hits: 1
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data